Abstract
We describe a clinical syndrome occurring after contrast medium injection in patients who previously received recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha 2A treatment for metastatic renal cancer. The clinical picture mimics many aspects of rIL-2-related systemic side effects. The patients were managed conservatively but the potential for severe manifestations can occur, requiring more intensive treatment.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Carcinoma, Renal Cell / therapy*
-
Contrast Media / adverse effects*
-
Drug Interactions
-
Humans
-
Immunotherapy
-
Interferon Type I / therapeutic use
-
Interleukin-2 / adverse effects*
-
Interleukin-2 / therapeutic use
-
Kidney Neoplasms / therapy*
-
Neoplasm Metastasis
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
Substances
-
Contrast Media
-
Interferon Type I
-
Interleukin-2
-
Recombinant Proteins